Chiral dinapsoline

Details Chiral dinapsoline Chiral dinapsoline

2006-08-15

2006-08-15

Davis, Zinna N. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S061000

Reexamination Certificate

active

07091212

ABSTRACT:
The present invention relates to the preparation of the optical isomer (R)-(+)-8,9-dihydroxy-2,3,7,11b-tetrahydro-1H-napth[1,2,3-de]isoquinoline. This invention also relates to the use of pharmaceutical compositions comprising (R)-(+)-8,9-dihydroxy-2,3,7,11b-tetrahydro-1H-napth[1,2,3-de]isoquinoline for use for the treatment of movement disorders.

REFERENCES:
patent: 5047536 (1991-09-01), Nichols
patent: 5420134 (1995-05-01), Nichols et al.
patent: WO 97/02513 (1996-02-01), None
patent: WO 97/06798 (1997-02-01), None
patent: WO 97/06799 (1997-02-01), None
patent: WO 02/13827 (2002-02-01), None
D. Ghosh, et al.,J. Med. Chem.39: 549-555 (1996).
R. Mattson, et al.,ACS Organic Division,Boston Abstract No. 059 (1998).
C.P. Manik, et al.,J. Neurochemistry,51: 391-397 (1988).
K.D. Burris, et al.,Neuropsychopharmacology,vol. 12, pp. 335-345 (1995).
Remington's Pharmaceutical Sciences, Mack Publishing Comp., Easton, P.A. 17th edition, 1985.
Pearson, et al., inJ. Heterocycl. Chem., vol. 6(2), pp. 243-245 (1969).
Sing-Yuen Sit et al., “(+) Dinapsoline: An Efficient Synthesis and Pharmacological Profile of a Novel Dopamine Agonist”,Journal of Medicinal Chemistry, vol. 45, No. 17, pp. 3660-3668, (2002).

Affiliated with

Also associated with

Rating

Chiral dinapsoline does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chiral dinapsoline, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chiral dinapsoline will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3665365